In addition, according to a retrospective statistical analysis, higher expression of THRα1 showed a significantly worse disease free survival (DFS), while THRα2 expression may predict a better outcome of BC [43,45] Recently, Wahdan-Alaswad et al. [18] reported that TH treatment significantly and independently reduced disease-free and breast cancer-specific overall survival in steroid receptor positive BC patients in a long-term observational study. The gene discussed is THRA; the disease is breast cancer.